Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Site Open-Label Safety Extension Study of Manualized MDMA-Assisted Psychotherapy for the Treatment of Participants With Posttraumatic Stress Disorder

NCT04714359 is registered in ClinicalTrials.gov with Resilient Pharmaceuticals as lead sponsor.

NCT NCT04714359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04714359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Site Open-Label Safety Extension Study of Manualized MDMA-Assisted Psychotherapy for the Treatment of Participants With Posttraumatic Stress Disorder
Lead sponsor
Resilient Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
March 8, 2021
Completion date
November 6, 2023
Enrollment
87 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd